Piper Sandler Initiates Coverage On Palisade Bio with Overweight Rating, Announces Price Target of $25
Benzinga Newsdesk 10 months ago
NewsPrice TargetInitiationAnalyst Ratings
Piper Sandler analyst Yasmeen Rahimi initiates coverage on Palisade Bio (NASDAQ:PALI) with a Overweight rating and announces Price Target of $25.
Piper Sandler analyst Yasmeen Rahimi initiates coverage on Palisade Bio (NASDAQ:PALI) with a Overweight rating and announces Price Target of $25.